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CirrhosisAbstract Background: Non-alcoholic fatty liver disease (NAFLD) is very common and serious
disease. It begins as a simple hepatosteatosis but can progress to cirrhosis. The early detection of
portal hypertension (HT) can be helpful in the management of these patients.
Aims: To evaluate radiologic findings of portal hypertension at computed tomography (CT) of
patients with non-alcoholic fatty liver disease for early diagnosis.
Methods and materials: Images of 225 cases who underwent non-enhanced abdominal CT were
reviewed. The patients with the difference between hepatic and splenic attenuation (CT L-S)
> 10 were enrolled in hepatosteatosis group. The remainings formed control group. The relation-
ship between two groups about diameters of portal and splenic veins, craniocaudal (CC) span of
liver, splenic index, caudate lobe/right lobe (C/RL) ratio was analyzed statistically by Mann–
Whitney U Test and Student’s t-test.
Results: Total 213 cases, as hepatosteatosis (n= 149) and control (n= 64) groups, were involved
in this study. Liver CC span, splenic index and C/RL ratio between two groups were found to be
statistically significant (p< 0.01).
Conclusions: The splenic index and C/RL ratio are important findings of portal HT and fibrosis.
CT imaging can be beneficial for diagnosis and treatment of NAFLD patients.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Hepatosteatosis is accumulation of fat more than 5% of liver
weight in hepatocytes (1). Hepatosteatosis without history of
alcohol consumption is called non-alcoholic fatty liver disease
(NAFLD), which is a common cause of chronic liver disease
Fig. 1 The measurements of ROIs at liver and spleen and C/RL
ratio were shown in 51 years-old male with NAFLD.
Fig. 2 Hepatosteatosis was demonstrated with the measure-
ments of ROIs at liver and spleen in 64 years old female with
NAFLD.
708 F. Kulali et al.(1,2). NAFLD, beginning only as simple steatosis, generally
induces non-alcoholic steatohepatitis (NASH), and eventually
may lead to cirrhosis and hepatocellular carcinoma (HCC)
(3,4).
Early detection of NAFLD is necessary to prevent progres-
sion. Percutaneous liver biopsy is required for accurate diagno-
sis of NASH; however, imaging studies can be helpful in
avoiding unnecessary biopsies (5–7). After exclusion of viral
hepatitis and alcoholic liver disease with laboratory findings
and history, diagnosis of NAFLD including NASH, can be
done by imaging modalities (8–10). Ultrasound (US), com-
puted tomography (CT) or magnetic resonance imaging
(MRI) can detect the existence of steatosis (8–10). US is a
non-invasive and cost-effective method for detection of hep-
atosteatosis; however, the visual grading of hepatosteatosis
with US depends on the experience of the observer (3). Non-
enhanced CT is a non-invasive procedure, which allows quan-
titative measurements for accurate diagnosis of hepatosteatosis
(3,8,10). MRI can also be performed for the quantitative esti-
mations of hepatosteatosis, but it is not cost-effective and
scanning time is longer (5,11).
Despite many studies on evaluation of hepatosteatosis by
US and CT in patients with NASH, a few studies analyzed
the progression of NAFLD to portal hypertension (HT) on
imaging (2,3). Our study was performed to investigate the role
of CT on detection of development of portal HT in NAFLD
patients. For this reason, we evaluated the CT images of
NALFD patients for portal HT findings based on quantitative
measurements.
2. Materials and methods
Between July 2011 and November 2012, 225 consecutive
patients who underwent non-enhanced abdominal CT with
nonspecific symptoms, were reviewed at a single institution
from PACS (Picture Archiving and Communications System).
The exclusion criteria for this study were as follows: (a) the
patients with liver mass; (b) the positive laboratory findings
for viral hepatitis; (c) the patients with history of alcohol con-
sumption. The remaining 213 cases were included in our study.
The patients who had hepatosteatosis, constituted the study
group. The patients without hepatosteatosis were evaluated
as the control group. The CT images were examined by a radi-
ologist. All CTs were performed at a multi-slice helical scanner
(Somatom Sensation 40, Siemens Medical Solutions, Erlangen,
Germany). Scanning parameters for non-enhanced CT images
were as follows: tube voltage, 120 kVp; tube current, 20 mAs,
helical thickness, 2.5 mm, interval, 2.5 mm, pitch, 1.5 and
reconstruction slice thickness 1.25 mm.
3. Theory/calculation
For detection of hepatosteatosis, the difference of hepatic and
splenic attenuation (CT L-S) was used (10). The region of
interest (ROI) measurements at five segments of liver (seg-
ments V, VI, VII, VIII from right lobe and segment IVb from
left lobe) and at splenic zones (superior, middle, inferior) were
performed (Figs. 1 and 2). The mean attenuation values were
estimated. For each measurement, a 200 mm2 circle ROI was
used. ROIs were measured from parenchymal area without
vascularity, calcifications, visible biliary system and artifacts.The patients with CT L-S > 10 were enrolled in our study
group, and the remainings were reported as the control group.
For assessment of progression to portal HT, diameters of
portal and splenic veins, craniocaudal (CC) span of liver, sple-
nic index, and caudate lobe/right lobe (C/RL) ratio were esti-
mated (Fig. 3). The portal and splenic venous measurements
were done at the level of liver hilum and splenic hilum, respec-
tively. Splenic index was calculated by the formula of longitu-
dinal length  anterior posterior (AP) diameter  mediolateral
diameter. The mediolateral diameter was measured at the level
of splenic hilus. C/RL ratio was estimated by using technique
previously described (12). C/RL < 0.65 is accepted as normal.
Statistical analyses were performed using Number
Cruncher Statistical System (NCSS) 2007 and the Power Anal-
ysis and Sample Size (PASS) 2008 Statistical Software (Utah,
USA). Mann–Whitney U Test or Student’s t-test was used,
where appropriate, and p< 0.05 was used to determine statis-
tical significance.
4. Results
Total 213 cases, as study (n= 149) and control (n= 64)
groups, were involved in this study. Of 213 patients, 48%
Fig. 3 The measurements of ROIs at liver and spleen and C/RL
ratio were estimated in 45 years-old male with NAFLD.
Table 1 The mean values of measurements of the study and
control groups were shown. There were statistically significant
differences between two groups about liver span, C/RL ratio
and splenic index.
Parameters The study
group (mean)
The control
group (mean)
p
Liver span (mm) 186 173 0.001a,**
Splenic index 498 424 0.024b,*
Portal venous
diameter (mm)
12 12 0.310a
Splenic venous
diameter (mm)
7 8 0.164a
C/RL ratio 0.32 0.28 0.001a,**
a Student-t test.
b Mann–Whitney U Test.
* p< 0.05.
** p< 0.01.
Fatty liver, portal hypertension and computed tomography 709(n= 102) were women and 52% (n= 111) were men. In study
and control groups, the mean age was 49 and 52 years, respec-
tively. The mean age of control group was a little higher, but
not statistically significant (p> 0.05).
The mean liver CC spans in the study and control groups,
were 186.5 mm and 173.5 mm, respectively. Despite high mean
liver spans in both groups, there was a statistically significant
difference between two groups (p< 0.01). All C/RL ratios
were within normal limits in both groups. The mean C/RL
ratios were estimated 0.32 and 0.28 in the study and control
groups, respectively. The mean C/RL ratio of study patients
was significantly higher than that of the control group
(p< 0.01). The mean splenic indexes in the study and control
groups were 499 cc and 424 cc, respectively. The mean splenic
index was statistically higher in the study group (p< 0.05).
The splenic index that can be calculated accurately at CT, is
an important indicator of portal HT. The mean diameters of
portal and splenic veins were found to be 12 mm and 8 mm,
respectively, in both study and control groups (p> 0.05),
which showed no significant difference between two groups.
The distribution of mean values and statistically relationships
between groups are shown in Table 1.
5. Discussion
NAFLD is a common disease and defined as hepatosteatosis
without history of alcohol consumption (9). NAFLD can be
seen without symptoms or with elevated liver enzymes or more
severe forms such as fibrosis, liver failure, cirrhosis or HCC
(3,4). The accurate diagnosis is done by percutaneous liver
biopsy. Because it is an invasive method, we hypothesized that
CT can be used as a non-invasive method for early diagnosis of
portal HT in NAFLD. The imaging findings such as coarse
echogenity of liver, blunt liver edge, surface nodularity, cau-
date lobe hypertrophy, shrunken right lobe, increased diame-
ters of portal and splenic veins, splenomegaly, ascites, varices
are accepted as advanced fibrosis (4). CT is an effective method
for detection of these findings with quantitative measurements.
In this study, we emphasized that the demonstration of the
presence of portal HT at CT can be helpful for detection of
whether biopsy is required or not. So, the unneeded biopsiescan be avoided. The splenic index, portal and splenic venous
diameters, which were not searched before in hepatosteatosis
patients, were also investigated in this study. Liver spans, sple-
nic indexes and C/RL ratios in NAFLD patients were signifi-
cantly higher in study group. Therefore, it was shown that the
non-enhanced CT can be used efficiently for demonstration of
the presence of portal HT in NAFLD patients. Before decision
of biopsy, non-enhanced CT can easily be applied. Biopsy can-
didates can be selected accurately.
In previous studies, Boyce et al. and Saadeh et al. reported
that CT can be used as a screening tool for identifying hep-
atosteatosis (13,14). But, in contrast to our study, the evalua-
tion of progression to steatohepatitis and cirrhosis was not
investigated. The imaging features of portal HT were not
assessed.
To date, few studies have involved in the effects of US and
CT findings on determination of hepatosteatosis and fibrosis.
The roles of US and CT were examined on detection of steato-
sis and fibrosis in 118 NASH patients who underwent biopsy
(3). The sensitivities of both US and CT were decreased by
increasing fibrosis. Despite these limitations, US and CT were
found to be effective for detection of steatosis and fibrosis in
patients with NAFLD (3). In another study, the relationship
between US and CT findings and histopathological grade
and stage were investigated in 22 biopsy proven NASH
patients (15). They reported that the mean liver densities and
liver/spleen density ratio were statistically lower in their study
group when compared with the control group (p< 0.05). In
contrast to previous study (3), US was demonstrated as an
inadequate method to define histopathological severity in
NASH patients (15). They found a correlation between CT
attenuation of liver and histopathological grade (p< 0.05)
but not stage (15). In light of these studies, CT was used for
detection of portal HT in this study.
In the study by Oliva et al., CT findings of 68 patients with
NASH were analyzed (2). Of 68, 12 patients underwent liver
biopsy. As a result, NASH patients had statistically higher
CC liver span (p< 0.05) and C/RL ratio (p< 0.05) than those
of the controls (n= 9) (2). The similar results were achieved,
but, additionally, the splenic indexes were also higher in
NAFLD patients in our study. The number of patients was
smaller compared to our study group.
710 F. Kulali et al.Hitherto, to the best of our knowledge, none of the previ-
ous studies researched about the progression of portal HT with
measuring splenic index, diameters of portal and splenic veins
in NAFLD patients. In NAFLD patients, the splenic index is
accepted as an essential feature of portal HT. Our study is the
largest series that investigated the portal HT findings in
NAFLD patients at CT. There were statistically significant dif-
ference between groups according to CC liver span, splenic
index, C/RL ratio (p< 0.05). The higher CC liver span, sple-
nic index and C/RL ratio were noted as the findings of portal
HT in the study group. Therefore, the portal HT findings at
CT imaging in NAFLD patients can lead to biopsy for diagno-
sis of NASH. Unnecessary procedures may be prevented. The
limitation of this study was the lack of histopathological
results of NAFLD patients. Further investigations proven by
biopsy are needed.
6. Conclusions
NAFLD is a common and severe disease which may cause por-
tal HT and fibrosis. The early diagnosis of portal HT is impor-
tant. The splenic index and C/RL ratio that are crucial signs of
portal HT can be easily measured on CT in NAFLD patients.
So, as a non-invasive modality CT has an important role for
diagnosis and treatment of these patients additional to clinical
findings.
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